Le Lézard
Classified in: Health
Subjects: POL, AVO

Dialysis Patient Citizens Statement Following Supreme Court Decision in Marietta Memorial Hospital v. Davita


WASHINGTON, June 22, 2022 /PRNewswire/ -- Following the United States Supreme Court decision in the case of Marietta Memorial Hospital v. Davita, Dialysis Patient Citizens (DPC) Board of Directors President Andrew Conkling issued the following statement:

"DPC is deeply disappointed by today's Supreme Court decision," said DPC Board President Andrew Conkling. "Congress long ago reaffirmed privately-insured patients' right to continue on their employer-sponsored plan for 30 months. This played an important role in preserving patient choice and incentivizing insurers to detect and treat Chronic Kidney Disease. ESRD patients are among the most vulnerable Americans and face some of the largest health disparities. To allow these plans to shift patients to Medicare before the expiration of this period represents immediate and profound risks for kidney patients and their families across the nation. As the dissenting justices stated, Congress will have to fix a statute that the Court has broken. We will go back to Congress with other ESRD patient advocates to immediately clarify the rules once and for all."

CONTACT: Hannah Bracamonte, [email protected]

SOURCE Dialysis Patient Citizens


These press releases may also interest you

at 01:00
REGULATED INFORMATIONMay 10, 2024, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the "Company") Invitation to attend the annual and the extraordinary shareholders'...

at 00:16
WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043. This landmark achievement marks the world's first approval of an EB virus-related mRNA...

at 00:00
SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer (SCLC) for SNB-101 (API: SN-38), a new drug for polymer nanoparticle anticancer under clinical trial. SNB-101...

9 mai 2024
TCI Group is proud to be participating in Phase 1 of the Alliance for Water Stewardship (AWS) Impact Accelerator. Together we are working in Shanghai Jinshan with AWS Members and five other facilities to expand our knowledge, skills and networks to...

9 mai 2024
A research team led by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been awarded approximately $11 million over five years by the National...

9 mai 2024
Celltrion USA announced today that adalimumab-aaty, the company's high-concentration (100 mg/mL) and citrate-free formulation biosimilar to HUMIRA ® (adalimumab), is now available at a low wholesale acquisition cost (WAC). Adalimumab-aaty will be...



News published on and distributed by: